InSysBio to present posters at ASCPT 2024 Annual Meeting

events

Conference

March 6, 2024

InSysBio announces its participation in the ASCPT 2024 Annual Meeting which is to be held March 27-29, at the Broadmoor in Colorado Springs, CO. Tatiana Karelina, Head of Neurodegenerative Diseases modeling team, and Vladislav Leonov, CYTOCON DB team, will present 4 posters by InSysBio in frames of the Meeting, namely:

Thursday, March 28, 2024 5:00 PM – 6:30 PM MDT:

PII-014 "Unraveling IL9 serum distribution patterns: insights from the CYTOCON Database" by Vladislav Leonov, Ekaterina Mogilevskaya, Elita Gerasimuk, Nikolay Pervushin, Nail Gizzatkulov, Oleg Demin
PII-220 "Response to lymphocyte depleting and lymphocyte modulating therapies in different populations of patients with multiple sclerosis investigated by Quantitative Systems Pharmacology model" by Tatiana Karelina, Maria Myshkina, Oleg Demin. The poster will be denoted by a Top Poster Ribbon
PII-221 "Tetravalency impact on bispecific antibody-achieved receptor occupancy and target downregulation: estimation by translational PK/RO model of CTX8371 antibody" by Veronika Musatova, Oleg Demin, Oleg Demin Jr, Dmitry Shchelokov
PII-222 "Validation of a Quantitative Systems Pharmacology model for Chronic Hepatitis B" by Galina Lebedeva¹, Alexander Stepanov¹, Veronika Musatova², Oleg Demin¹, Loveleena Bansal³, Cibele V. Falkenberg³, Valeriu Damian³

Affiliation: (1) InSysBio UK, Edinburgh, UK; (2) InSysBio CY, Paphos, Cyprus; (3) GSK, Collegeville, PA, US

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	July 2017	→
Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14 1. 14 Jul 2017 18:49 To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.	15	16
17	18	19	20	21	22	23
24	25 1. 25 Jul 2017 13:50 InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc. Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc. 2. 25 Jul 2017 17:37 InSysBio will present at the American Conference on Pharmacometrics (ACoP8)! Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.	26	27	28	29	30
31

Upcoming Events

Mo	Tu	We	Th	Fr	Sa	Su
←	July 2017					→
					1	2
3	4	5	6	7	8	9
10	11	12	13	14 1. 14 Jul 2017 18:49 To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.	15	16
17	18	19	20	21	22	23
24	25 1. 25 Jul 2017 13:50 InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc. Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc. 2. 25 Jul 2017 17:37 InSysBio will present at the American Conference on Pharmacometrics (ACoP8)! Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.	26	27	28	29	30
31